上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2021 年限制性股票激励计划 调整、预留授予部分第三个归属期归属条件成就及 部分已授予尚未归属限制性股票作废相关事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 部分已授予尚未归属限制性股票作废相关事项的 法律意见书 01F20245294 致：上海阿拉丁生化科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海阿拉丁生化科技股份有限公司 （以下简称"公司"或"阿拉丁"）的委托，并根据公司与本所签订的法律服务合同，作为公 司 2021 年限制性股票激励计划（以下简称"本次激励计划"）的法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称" ...

阿拉丁公告，全资子公司上海客学谷网络科技有限公司拟以自有或自筹资金按比例购买喀斯玛科技员工 持股平台嘉兴科服投资合伙企业全体合伙人分别持有的嘉兴科服40%的财产份额，交易价格合计为 9728.96万元；拟以自有或自筹资金按比例购买嘉兴科进企业管理咨询合伙企业全体合伙人分别持有的 嘉兴科进40%财产份额，交易价格为3587.21万元。本次收购合计对价1.33亿元。 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2024年度持续督导工作现场检查报告 上海证券交易所： 根据《上海证券交易所上市公司自律监管指引第11号——持续督导》等有关法 律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为上海阿拉丁 生化科技股份有限公司（以下简称"阿拉丁"、"公司"）持续督导阶段的保荐人， 于2025年10月14日对公司2024年度的规范运作情况进行了现场检查，现将现场检查 的有关情况报告如下： 一、本次现场检查的基本情况 二、现场检查的具体事项及意见 1 （一）公司治理和内部控制情况 核查情况：现场检查人员查阅了公司的公司章程、三会议事规则，收集了股东 大会、董事会和监事会的会议通知、决议和记录等资料，核对了公司相关公告，并 查阅了公司其他内控制度。 核查意见：经核查，2024年度，公司的章程和公司治理制度完备、合规，相关 制度得到有效执行，公司的董事、监事和高级管理人员能够按照有关规定的要求履 行责任，内部控制制度得到有效执行。 （一）保荐人：西部证券股份有限公司 （二）保荐代表人：滕晶、李晶 （三）现场检查时间：2025年10月14日 （四）现场检查人员：滕晶 ...

Core Viewpoint - Aladdin (688179.SH) experienced a decline of 3.96%, trading at 12.38 yuan, with a market capitalization of 4.1 billion yuan [1] Group 1: Shareholder Actions - The company announced that as of October 13, 2025, it received a notification from shareholder Jingzhen Culture regarding the completion of its share reduction plan [1] - Jingzhen Culture reduced its holdings by 2.4 million shares, which represents 0.7216% of the company's total share capital at the time the reduction plan was disclosed [1]

Core Viewpoint - Aladdin's stock has experienced a decline of 2.02% on October 14, with a current price of 12.63 CNY per share, reflecting a total market capitalization of 4.201 billion CNY. The company has seen a year-to-date stock price increase of 11.44%, but has faced recent declines over various trading periods [1][2]. Financial Performance - For the first half of 2025, Aladdin reported a revenue of 275 million CNY, representing a year-on-year growth of 15.45%. However, the net profit attributable to shareholders decreased by 39.79% to 28.4635 million CNY [2]. - Cumulative cash dividends since the A-share listing amount to 241 million CNY, with 150 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 22.88% to 12,500, while the average circulating shares per person decreased by 2.42% to 26,670 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by China Europe Medical Health Mixed A and an increase by China Europe Responsibility Investment Mixed A [3]. Company Overview - Aladdin Biochemical Technology Co., Ltd. was established on March 16, 2009, and went public on October 26, 2020. The company specializes in the research, development, production, and sales of reagents, with 96.96% of its revenue coming from scientific research reagents [1]. - The company operates within the basic chemical industry, specifically in the chemical products sector, and is associated with various concepts including ursodeoxycholic acid and synthetic biology [1].

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Shanghai Aladdin Biochemical Technology Co., Ltd, specifically the employee shareholding platform, Jingzhen Culture, which has reduced its holdings in the company. Group 1: Shareholder Holding Situation - Before the reduction plan, Jingzhen Culture held 9,781,190 shares, accounting for 2.94% of the company's total share capital, with shares obtained prior to the company's IPO and through capital reserve transfers [2][4]. Group 2: Reduction Plan Implementation Results - The reduction plan, disclosed on June 21, 2025, allowed Jingzhen Culture to reduce its holdings by up to 2,400,000 shares, representing no more than 0.7216% of the total share capital, with the reduction period set from July 14, 2025, to October 13, 2025 [3][6]. - As of the announcement date, Jingzhen Culture successfully reduced its holdings by 2,400,000 shares, which is exactly 0.7216% of the total share capital of 332,602,199 shares at the time of the plan disclosure [3][8].

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-063 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 减持计划的实施结果情况 公司于 2025 年 6 月 21 日披露《关于公司股东减持股份计划公告》（公告编 号：2025-047），晶真文化拟通过集中竞价方式减持其所持有的公司股份合计不 超过 2,400,000 股（含本数），拟减持股份占公司总股本的比例不超过 0.7216%。 计划减持期限为自减持计划披露之日起 15 个交易日后的 3 个月内（即自 2025 年 7 月 14 日起至 2025 年 10 月 13 日）。减持价格按市场价格确定，若公司在上 述减持计划实施期间发生派发红利、送红股、转增股本、增发新股或配股等股本 除权、除息事项的，则上述减持计划将作相应调整。 2025 年 10 月 13 日，公 ...

Core Points - Aladdin (688179.SH) announced the completion of a share reduction plan by its shareholder, Jingzhen Culture, on October 13, 2025 [1] - Jingzhen Culture reduced its holdings by 2.4 million shares, which represents 0.7216% of the company's total share capital at the time of the reduction plan announcement [1]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、可转债发行上市概况 （一）可转债发行上市情况 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 可转债转股结果暨股份变动公告 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 15 日向不特定对象发行了 387.40 万张可转换公司债券，每张面值 100 元，发行总额 38,740.00 万元。 累计转股情况：上海阿拉丁生化科技股份有限公司（以下简称"公司"） 向不特定对象发行可转换公司债券"阿拉转债"自 2022 年 9 月 21 日开 始转股，截至 2025 年 9 月 30 日，"阿拉转债"累计有人民币 471,000 元已转换为公司股票，转股数量为 16,303 股，占"阿拉转债"转股前 公司已发行股份总额的 0.011537%。 未转股可转 ...